Tag

Zepbound

All articles tagged with #zepbound

business3 days ago•3 min saved

CagriSema lags Zepbound as Novo Nordisk presses toward FDA decision

Novo Nordisk’s obesity drug CagriSema delivered slightly less weight loss than Lilly’s Zepbound in an 84-week phase 3 trial, raising questions about its market potential ahead of a late-2026 FDA decision and a possible 2027 launch. Novo defends the drug’s efficacy and points to additional trials (REDEFINE 11 and a higher-dose study) while analysts warn it may struggle to gain share from Zepbound, signaling potential reliance on future deals to bolster its pipeline.

via CNBC|

#business #cagrisema #novo-nordisk

business4 days ago•2 min saved

Lilly rolls out monthly-dose Zepbound pen to simplify obesity therapy

Eli Lilly introduced a KwikPen that delivers four weekly doses of Zepbound in one monthly injection, priced from $299 per month on LillyDirect, with FDA labeling expanded to include the multi-dose device to support Zepbound’s dominant position in the obesity-drug market.

via CNBC|

#business #eli-lilly #kwikpen

business23 days ago•21 min saved

Lilly's weight‑loss drugs drive strong quarter, lift 2026 outlook and stock

Eli Lilly posted 4Q25 sales of $19.3 billion, up 43%, driven by Zepbound at $4.3 billion (up 123%) and Mounjaro at $7.4 billion (up 110%), beating estimates with $11.7 billion from the two drugs. The company guided 2026 revenue of $80–83 billion and adjusted EPS of $33.50–$35.00, signaling ongoing growth even as Novo Nordisk anticipates a 5–13% 2026 decline. Lilly also struck a most‑favored‑nations deal for discounts via TrumpRx, and its stock rose in premarket trading.

via MarketWatch|

#business #earnings #lilly

business23 days ago•18 min saved

Lilly fuels growth with Q4 2025 results, raises 2026 outlook to $80–83B

Eli Lilly reported Q4 2025 revenue of $19.3B, up 43% y/y, with GAAP EPS of $7.39 and non-GAAP EPS of $7.54, driven by strong demand for Mounjaro and Zepbound. The company highlighted regulatory progress (FDA approval of Kwikpen for tirzepatide and expanded Jaypirca indication) and a 2026 revenue guidance of $80–$83B with non-GAAP EPS of $33.50–$35.00, along with ongoing obesity/diabetes pipeline developments and a U.S. government agreement to expand access to obesity medicines.

via Eli Lilly|

#2026-guidance #business #lilly

business24 days ago•2 min saved

Lilly Surges on GLP-1 Demand, Sets 2026 Revenue Outlook

Eli Lilly beat Q4 estimates with adjusted EPS of $7.54 and revenue of $19.29B (up 43%), and issued 2026 guidance of $80-83B in revenue and $33.50-35 in EPS, powered by robust GLP-1 demand for Zepbound and Mounjaro. U.S. sales reached $12.9B with volume up about 50% while prices moderated. Lilly faces competition from Novo Nordisk and highlighted pricing steps under a 2026 deal with Medicare/Medicaid and a direct-to-consumer TrumpRx platform, with most pricing moves expected early in 2026 and volume growth ramping in the second half. The company is also pursuing an oral weight-loss drug, orforglipron, later this year.

via CNBC|

#business #earnings #eli-lilly

business1 month ago•2 min saved

Novo’s New Wegovy Pill Surges Out of the Gate

Novo Nordisk’s oral Wegovy is off to a strong start, with Week 2 prescriptions around 18,000–20,000, reportedly higher than the initial weeks of injectable Wegovy and Lilly’s Zepbound. Analysts say the rapid uptake could help Novo regain obesity market share as it faces competition from Lilly’s orforglipron and Zepbound’s dominance; the pill is priced at $149 per 1.5 mg dose (cash) with insured patients potentially paying as low as $25 per month, and Novo’s stock has risen about 20% this year in response.

via Fierce Pharma|

#business #novo-nordisk #obesity

personal-finance1 month ago•23 min saved

Half of GLP-1 users abandon injections as weight loss returns prompt new maintenance options

New research finds about 50% of people who stop GLP-1 weight-loss drugs Wegovy or Zepbound regain all the weight they lost within two years, with cost and gastrointestinal side effects driving discontinuation. As patients seek durable results, doctors point to a mix of options—from bariatric procedures and endoscopic sleeve gastroplasty to new oral GLP-1 pills like Wegovy’s pill and Lilly’s orforglipron—though real-world adherence and insurance coverage remain uncertain.

via MarketWatch|

#glp-1 #obesity #personal-finance

healthcare1 month ago•1 min saved

Eli Lilly's Zepbound and Taltz Combo Shows Promise for Psoriatic Arthritis and Obesity

Eli Lilly's drug Zepbound, when combined with its immunology therapy Taltz, showed promise in reducing symptoms of psoriatic arthritis in obese patients, suggesting potential new uses for the weight loss drug, though its impact on prescribing patterns remains uncertain.

via statnews.com|

#eli-lilly #healthcare #immunology

health1 month ago•18 min saved

Lilly's Zepbound and Taltz Combo Shows Promise for Psoriatic Arthritis and Obesity

Eli Lilly's Phase 3b trial shows that combining Taltz (ixekizumab) and Zepbound (tirzepatide) significantly improves outcomes in adults with psoriatic arthritis and obesity, meeting primary and secondary efficacy endpoints and suggesting a potential new integrated treatment approach.

via Eli Lilly|

#clinical-trial #health #obesity

health-and-medicine2 months ago•4 min saved

Eli Lilly's New Weight-Loss Drugs Show Promising Results in Phase 3 Trials

Eli Lilly's new obesity pill helps patients maintain weight loss after switching from injections like Wegovy and Zepbound, with promising trial results suggesting it could serve as a needle-free long-term treatment option, potentially capturing significant market share in the growing weight loss drug industry.

via CNBC|

#elililly #health-and-medicine #obesity

business2 months ago•2 min saved

Eli Lilly reduces Zepbound weight-loss drug prices amid industry trend

Eli Lilly has reduced the cash prices of its Zepbound weight loss drug vials on its direct-to-consumer platform, making the medication more accessible amid industry price cuts and government efforts to lower drug costs. Starting at $299 per month for the initial dose, the prices are now more affordable compared to the previous $349, aiming to improve access for patients facing high list prices and limited insurance coverage.

via CNBC|

#business #eli-lilly #pharmaceuticals

health3 months ago•6 min saved

Trump Announces Deals to Lower Costs and Expand Coverage for Obesity Drugs

President Trump announced a deal with Eli Lilly and Novo Nordisk to expand coverage and lower prices for obesity drugs Wegovy and Zepbound, including Medicare coverage starting next year and phased price reductions for uninsured patients, aiming to improve access and affordability of these effective treatments.

via AP News|

#drug-pricing #health #obesity-drugs

business4 months ago•2 min saved

Eli Lilly's Revenue Soars with Top-Selling Diabetes and Weight Loss Drugs

Eli Lilly's obesity and diabetes drugs Mounjaro and Zepbound generated over $10 billion in Q3, fueling a booming market and a bidding war, with Novo Nordisk planning to acquire Metsera in a deal potentially worth up to $9 billion, highlighting intense competition in the GLP-1 receptor agonist space.

via Yahoo Finance|

#business #diabetes-treatments #eli-lilly

business4 months ago•1 min saved

Eli Lilly's Sales Surge and Raised Guidance Driven by Mounjaro and Zepbound

Eli Lilly's Q3 earnings surpassed expectations with $7.02 per share on $17.6 billion in sales, driven by strong sales of diabetes drug Mounjaro and weight-loss drug Zepbound, leading to an upward revision of annual guidance and a 3.9% rise in stock price.

via Investor's Business Daily|

#business #earnings #eli-lilly

business4 months ago•1 min saved

Eli Lilly Surges Ahead with Strong Sales and Raised Guidance

Eli Lilly exceeded earnings and revenue estimates in Q3, driven by strong sales of weight loss drug Zepbound and diabetes treatment Mounjaro, leading to an upward revision of its full-year outlook and a 5% premarket stock increase.

via CNBC|

#business #eli-lilly #guidance